Skip to Content

'
Felipe Samaniego, M. D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M.D. Anderson Cancer Center
7455 Fannin St
Unit 903
Houston, TX 77054
Room Number: SCR2.2026
Phone: 713-792-3510
Fax: 713-563-7314

Education & Training

Degree-Granting Education

1983 Harvard Medical School, Boston, MA, MD, Medicine
1983 Harvard School of Public Health, Boston, MA, MPH, Health Services
1978 New Mexico State University, Las Cruces, NM, BS, Biology

Postgraduate Training

1990-1995 RESEARCH FELLOW, Cell Biology and Metabolism Branch, National Institute of Child Health and Human Development, NIH, Bethesda, MD
1986-1990 CLINICAL FELLOW, Hematology-Oncology, Hematology-Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
1984-1986 RESIDENT, University of Colorado Health Sciences Center, Denver, CO
1983-1984 INTERN, University of Colorado Health Sciences Center, Denver, CO

Board Certifications

1989 American Board of Medical Oncology
1986 American Board of Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Immunology, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2003-2006
Assistant Professor, Human Virology, Institute of Human Virology, University of Maryland Medical Center, Maryland, MD, 1996-1999

Honors and Awards

2011 US News and World Report Top Docs
2002 AACR-MICR Council Member, AACR-MICR
1989 Daland Fellowship, Alternate Fellow
1989 Robert Wood Johnson Foundation Fellow

Selected Publications

Peer-Reviewed Original Research Articles

1. Zhu H, Berkova Z, Mathur R, Sehgal L, Khashab T, Tao RH, Ao X, Feng L, Sabichi AL, Blechacz B, Rashid A, Samaniego F. HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer. Mol Cancer Res 13(5):809-18, 5/2015. e-Pub 2/12/2015. PMID: 25678597.
2. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 3/2015. e-Pub 9/28/2014. PMCID: PMC4344896.
3. Braun FK, Mathur R, Sehgal L, Wilkie-Grantham R, Chandra J, Berkova Z, Samaniego F. Inhibition of Methyltransferases Accelerates Degradation of cFLIP and Sensitizes B-Cell Lymphoma Cells to TRAIL-Induced Apoptosis. PLoS One 10(3):e0117994, 2015. e-Pub 3/4/2015. PMCID: PMC4349737.
4. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. e-Pub 6/18/2014. PMID: 24943107.
5. Sehgal L, Mukhopadhyay A, Rajan A, Khapare N, Sawant M, Vishal SS, Bhatt K, Ambatipudi S, Antao N, Alam H, Gurjar M, Basu S, Mathur R, Borde L, Hosing AS, Vaidya MM, Thorat R, Samaniego F, Kolthur-Seetharam U, Dalal SN. 14-3-3γ meditated transport of plakoglobin to the cell border is required for the initiation of desmosome assembly in vitro and in vivo. J Cell Sci 127(Pt 10):2174-88, 5/15/2014. e-Pub 3/7/2014. PMID: 24610948.
6. Nasser QJ, Pfeiffer ML, Romaguera J, Fowler N, Debnam JM, Samaniego F, El-Sawy T, McLaughlin P, Bakhoum MF, Esmaeli B. Clinical Value of Magnetic Resonance Imaging and Other Baseline Testing for Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma. Leuk Lymphoma 55(5):1013-7, 5/2014. e-Pub 8/28/2013. PMID: 23879202.
7. Sehgal L, Mathur R, Braun FK, Wise JF, Berkova Z, Neelapu S, Kwak LW, Samaniego F. FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. Leukemia. e-Pub 4/3/2014. PMID: 24811343.
8. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 4/2014. e-Pub 1/6/2014. PMID: 24386943.
9. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 1/2014. e-Pub 12/11/2013. PMCID: PMC3922714.
10. Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera J, Samaniego F, Silverman JA, Sarris A, Cabanillas F. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol 162(5):631-8, 9/2013. e-Pub 6/27/2013. PMID: 23802738.
11. Wise JF, Berkova Z, Mathur R, Zhu H, Braun FK, Tao RH, Sabichi AL, Ao X, Maeng H, Samaniego F. Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. Blood. e-Pub 4/18/2013. PMID: 23599269.
12. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk, 4/2013. PMID: 23276888.
13. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP. Clin Lymphoma Myeloma Leuk, 2/2013. PMID: 23137719.
14. Oellers P, Savar A, Samaniego F, Pro B, Esmaeli B. Second-Line 90Yttrium-Ibritumomab Tiuxetan (Zevalin) in a Patient With Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma Refractory to Rituximab. Ophthal Plast Reconstr Surg 28(6):e145-6, 11/2012. PMID: 22820440.
15. Daniluk U, Kerros C, Tao RH, Wise JF, Ao X, Berkova Z, Samaniego F. The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematopoietic cancer cells. J Exp Clin Cancer Res 31(1):69, 8/2012. PMID: 22929310.
16. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716-23, 7/2012. PMID: 22677155.
17. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 6/2012. PMID: 22015451.
18. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood, 6/2012. PMID: 22586182.
19. Batty N, Hagemeister FB, Feng L, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study. Leuk Lymphoma 53(5):801-6, 5/2012. PMID: 22023528.
20. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Shabib Dabaja B, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood, 3/2012. PMID: 22371887.
21. Kojima K, Duvvuri S, Ruvolo V, Samaniego F, Younes A, Andreeff M. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. Cancer 118(4):1023-31, 2/2012. PMID: 21761401.
22. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F, Vega F. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 30(49):4874-86, 12/2011. PMCID: PMC3165099.
23. Wang J, Han F, Wu J, Lee SW, Chan CH, Wu CY, Yang WL, Gao Y, Zhang X, Jeong YS, Moten A, Samaniego F, Huang P, Liu Q, Zeng YX, Lin HK. The role of Skp2 in hematopoietic stem cell quiescence, pool size, and self-renewal. Blood 118(20):5429-38, 11/2011. PMCID: PMC3217347.
24. Tao RH, Berkova Z, Wise JF, Rezaeian AH, Daniluk U, Ao X, Hawke DH, Karp JE, Lin HK, Molldrem JJ, Samaniego F. PMLRARα binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo. Blood 118(11):3107-18, 9/2011. PMID: 21803845.
25. Fanale M, Fayad L, Pro B, Samaniego F, Liboon MJ, Nunez C, Horowitz S, Anderlini P, Popat U, Ji Y, Kwak LW, Younes A. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol 154(2):284-6, 7/2011. PMID: 21517809.
26. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-8, 7/2010. PMID: 20528872.
27. Ho HH, Savar A, Samaniego F, Manning J, Kasyan A, Pro B, Esmaeli B. Treatment of benign lymphoid hyperplasia of the orbit with rituximab. Ophthal Plast Reconstr Surg 26(1):11-3, Jan-Feb, 1/2010. PMID: 20090476.
28. Berkova Z, Tao RH, Samaniego F. Milatuzumab - a promising new immunotherapeutic agent. Expert Opin Investig Drugs 19(1):141-9, 2010. PMID: 19968579.

Invited Articles

1. Samaniego FS, Matias KP. Studies of the Viral Origins of Some Cancers Lead to New Prevention Treatment Stratigies, 2004.
2. Pati S, Lee Y, Samaniego F. Urinary proteins with pro-apoptotic and anti-tumor activity. Apoptosis 5(1):17-24, 2/2000. PMID: 11227487.

Abstracts

1. Thomas SK, Haygood TM, Qazilbash MH, Melendez AG, Galvis R, Delasalle KB, Feng L, Richards TA, Samaniego F, Wang L, Shah JJ, Orlowski RZ, Weber DM. . A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM). Blood(ASH Meeting Abstract). American Society of Hematology (#4396), 12/2013.
2. Samaniego F, Romaguera JE, Fowler Nathan, Fanale MA, Shah JJ, McLaughlin P, Pro B, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu S, Kwak LW. A Single Center Phase II Trial Of 90yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease. Blood (ASH Meeting Abstract) (#4396), 12/2013.
3. Berkova Z, Ao X, Braun FK, Wise JF, Sehgal L, Samaniego F. CD74 Interferes With The Expression Of Fas Receptor On The Cell Surface. Blood (ASH Meeting Abstract). (#4263), 12/2013.
4. Oki Y, Noorani M, Davis RE, Neelapu SS, Rodriguez A, Hagemeister FB, Fowler N, Wang M, Fanale MA, Samaniego F, Dabaja BS, Pinnix C, Kwak LW, Romaguera JE, Khouri I, Westin JR, and Fayad LE. Double Hit Lymphoma: M.D. Anderson Experience. Blood (ASH Meeting Abstract) (#1776), 12/2013.
5. Braun FK, Mathur R, Sehgal L, Berkova Z, and Samaniego F. Histone 3 Methyltransferase (EZH2) Inhibition Enhances TRAIL-Induced Apoptosis In Mantle Cell Lymphoma Cells By Accelerated cFLIP Degradation. Blood (ASH Meeting Abstract). (#4425), 12/2013.
6. Hagemeister FB, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Pro B, Romaguera JE, Samaniego F, Silverman JA, Sarris AH, Cabanillas F. Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo®) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas. Blood (ASH Meeting Abstract) (#3033), 12/2013.
7. Samaniego F, Mathur R, Berkova Z, Braun FK. Histone 3 methyltransferase (EZH2) inhibition results in accelerated caspase-8 processing and enhances TRAIL-induced apoptosis in mantle cell lymphoma cells. 12th International Conference on Malignant Lymphoma, 6/2013.
8. Samaniego F, Wise J, Tao RH, Zhu H, Ao X, Chen Z, Zhuang W, Braun FK, Mathur R, Romaguera JE, Fayad L, Wang M, McLaughlin P, McDonnell TJ, Patel K, Neelapu SS, Kwak LW, Berkova Z. Regulation of Fas-mediated Apoptosis by Nucleolin in B-cell Lymphomas. 12th International Conference on Malignant Lymphoma, 6/2013.
9. Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Orlowski RZ, Wang M, Turturro F, Oki Y, Lacerte LC, Samaniego F. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. Blood (ASH Meeting Abstract) 120 (#901), 11/2012.
10. Tao RH, Berkova Z, Wise JF, Zhu H, Ao X, Chen Z, Zhuang W, Braun FK, Mathur R, Samaniego F. Mechanism of Regulating Fas Signaling by Promyelocytic Leukemia Protein (PML) and Its Dominant-Negative Mutant PMLRARα. Blood (ASH Meeting Abstract) 120(21) (#1327), 11/2012.
11. Westin JR, Chu F, Fayad LE, Kwak LW, Fowler NH, Romaguera JE, Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, Neelapu SS. Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Blood (ASH Meeting Abstract) 120 (#793), 11/2012.
12. Fanale MA, Lai CM, Rimes SA, Ramirez MM, Hagemeister FB, Fowler NH, Younes A, Fayad LE, Rodriguez MA, Turturro F, Samaniego F, Romaguera JE, Levin VA, Horowitz SB, Woolery JE, Milbourne A. Positive Maternal-Fetal Outcomes with Treatment of Lymphoma During Pregnancy: UT MD Anderson Cancer Center Prospective Experience. Blood (ASH Meeting Abstract) 120 (#3670), 11/2012.
13. ki Y, Westin JR, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. Blood ASH Meeting Abstracts (#38707), 11/2012.
14. Samaniego F, Wise JF, Tao RH, Zhu H, Ao X, Chen Z, Zhuang W,Braun FK, Mathur R, Romaguera JE, Fayad L, Wang M, Peter McLaughlin PM, McDonnell TJ, Patel K, Neelapu SS, Kwak LW, Zuzana Berkova Z. Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin. Blood (ASH Meeting Abstract) 120 (#2406), 11/2012.
15. Oki Y, Chuang H, Chasen B, Pan T, Fanale MA, Dabaja BS, Fowler NH, Romaguera JE, Fayad JE, Hagemeister FB, Rodriguez MA, Neelapu SS, Samaniego F, Kwak LW, Younes A. The Prognostic Value of Interim PET Scan in Patients with Classical Hodgkin Lymphoma. Blood (ASH Meeting Abstract) 120 (#1529), 11/2012.
16. Fowler N, Zhang M, Wang Z, Muzzafar T, Harun N, Baladandayuthapani V, Sharma R, Delgado D, Wallace M, Heise C, Lacerte LC, Samaniego F, Davis ER, Neelapu SS. Activation of T and NK Cells Following Lenalidomide Therapy in Patients with Follicular Lymphoma. Blood (ASH Meeting Abstract) 120 (#1714), 2012.
17. Felipe Samaniego, Zuzana Berkova, Jillian F Wise, Celine Kerros, David H Hawke, Judith E. Karp, Hui-Kuan Li, Jeffrey J. Molldrem, and Rong-Hua Tao. . Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo. (ASH Meeting Abstract). Blood 116(3510), 2011.
18. Samaniego, Felipe. Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study. (ASH Meeting Abstract). Blood, 2011.
19. Felipe Samaniego, Zuzana Berkova, Jillian F Wise, Celine Kerros, PhD, David H Hawke, Judith E. Karp Hui-Kuan Lin, Jeffrey J. Molldrem and Rong-Hua Tao. PML and PMLRARα Interact with Fas to Regulate Fas-Mediated Apoptosis In Vivo. (ASH Meeting Abstract). American Society of Hematology(2451), December, 2011.
20. Samaniego, Felipe, Berkova, Z et al. PML and PMLRARa Interact with Fas to Regulate Fas-Mediated Apoptosis in vivo. Blood (ASH Meeting Abstract)(117 (2451)), 2011.
21. Andreef M, Kojima K, Padmanabhan S, Strair R, Kirschbaum M, Maslak P, Hillmen P, O'brien S, Samaniego F, Borthakur G, Konopleva M, Vassilev L, Nichols G. A multi-center, open-label, phase I study of single agent RG7112, A first in class p53-MDM2 antagonist, in patients with relapsed/refractory acute myeloid and lymphoid leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lympyhocytic lymphomas (CLL/SCLL). Blood 116(21):287, 2010.
22. Batty N, Hagemeister FB, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. ABVD chemotherapy with interferon for advanced-stage classical Hodgkin's lymphoma: A 10-year follow-up study. 2010 ASCO Annual Meeting Abstract (#8057), 2010.
23. Fowler NH, McLaughlin P, Hagemeister FB, Kwak LW, Fanale MA, Neelapu SS, Fayad L, Orlowski RZ, Wang M, Samaniego F. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. 2010 ASCO Annual Meeting Abstract (#8036), 2010.
24. Perini GF, Romaguera MA, Rodriguez B, Pra A, Younes NH, Fowler FB, Hagemeister F, Samaniego F, Kwak LW, Fayad L. Diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) involvement. Clinical presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at M. D. Anderson Cancer Center. 2010 ASCO Annual Meeting Abstract (#8072), 2010.
25. Tao RH, Berkova Z, Wise J, Daniluk U, Bai L, Ao X, Samaniego F. Direct suppression of Fas-Mediated apoptosis by PMLRARa through forming an apoptotic inhibitory complex with c-FLIP in acute promyelocytic leukemia. Blood 116(21):1297, 2010.
26. Okoroji GJ, de Padua Silva L, Saliba RM, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, Khouri I. Outcome in follicular lymphoma (FL) patients (pts) relapsing after autologous stem cell transplantation (ASCT): allografting vs. conventional therapy. Blood 116(21):1442, 2010.
27. Fanale MA, Chao-Ming L, McLaughlin P, romaguera J, Fayad L, Hagemeister F, Samaniego F, Rodriguez MA, Neelapu SS, Shah JJ, Kwak L, Dong W, Reed V, Dabaja BS, Popat U, younes A. Outcomes of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP. Blood 116(21):1159, 2010.
28. Manoukian GE, Hagemeister FB, McLaughlin P, Fayad L, Samaniego F, Goy A, Romaguera JE, Pro B, Cabanillas F, Rodriguez MA. Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL). 2010 ASCO Annual Meeting Abstract (#8078), 2010.

Manuals, Teaching Aids, Other Teaching Publications

1. Samaniego, F, Matias KP. Studies of the viral orgins of some cancers lead to new prevention, treatment strategies, 2004.
2. Samaniego F. The viral origins of lymphomas, 2002.

Last updated: 8/24/2015